Scientists at Regeneron Pharmaceuticals Inc. have found a new way to permanently stop allergy through a combination of therapies that prevents the production of antibodies in secondary lymphoid organs and in bone marrow. The approach was tested in vivo in cynomolgus monkeys and in a mouse model. Read More
Researchers from Shandong University reported on the preclinical characterization of A3B3C-1, a multifunctional agent for the treatment of Alzheimer’s disease (AD), taking into account its complex nature. With multiple processes involved in its pathogenesis, the exploration of multi-target drugs may fit to address the combination of pathological factors in AD. Read More
Recce Pharmaceuticals Ltd. has announced preclinical results from an in vivo study evaluating the antibacterial efficacy of its lead synthetic anti-infective candidate, R-327 (RECCE-327), against Neisseria gonorrhoeae in a mouse vaginal infection model. Read More
Researchers from Engrail Therapeutics Inc. presented preclinical data for the novel D2/3 receptor antagonist ENX-104, being developed for the treatment of depression. Read More
Nrx Pharmaceuticals Inc. has announced FDA clearance of its IND application for the use of NRX-101 (lurasidone hydrochloride/D-cycloserine) for the treatment of complicated urinary tract infections (cUTI). Read More
Researchers from Insilico Medicine Inc. reported on ISM-5043, a novel KAT6A inhibitor aimed to be used for the treatment of refractory ER+ breast cancer. Read More
Sperogenix Therapeutics Ltd. has identified nitrogen-containing five-membered heterocyclic derivatives acting as checkpoint kinase 1 (Chk1) inhibitors reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis and pulmonary arterial hypertension. Read More
Phosphoinositide 3-kinase (PI3K) is a key cell cycle pathway regulator involved in tumor growth and development. PI3Kα mutations in p110α subunit, H1047R and E542K/E545K are found in patients with several cancer types, including breast cancer and are targeted by approved drugs such as Piqray (alpelisib, Novartis AG). Read More
Avstera Therapeutics Corp. has received FDA clearance of its IND application for HDAC6 inhibitor AVS-100. Avstera intends to initiate a phase Ia/b trial in the first half of 2024 to evaluate AVS-100 alone and in combination with pembrolizumab in locally advanced or metastatic solid tumors. Read More
Samdolite Pharmaceuticals LLC has divulged prodrugs of cromoglicic acid reported to be useful for the treatment of inflammation and dermatological disorders. Read More
Kronos Bio Inc. has nominated a new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 transcription regulatory network (TRN), which is a key driver in multiple myeloma. Read More
Verastem Inc. has announced the nomination of an oral KRAS G12D inhibitor, VS-7375 (GFH-375), as the lead program from its discovery and development collaboration with Genfleet Therapeutics (Shanghai) Inc. Read More
Celgene Corp. has described heterocyclic protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of aging, autoimmune diseases, pain, asthma, inflammatory bowel diseases, AIDS, cancer and Alzheimer's disease, among others. Read More
Hemispherian AS has been granted NOK16 million (US$1.54 million) by the Research Council of Norway, which the company intends to use to support development of its drug candidates aimed at treating platinum-resistant ovarian cancers. Read More
Sirnaomics Ltd.'s subsidiary Rnaimmune Inc. has received IND clearance from the FDA to begin trials of RV-1770, an mRNA vaccine targeting the human respiratory syncytial virus (RSV) to prevent RSV infection in adults. Rnaimmune will conduct a phase I study of RV-1770 administered intramuscularly in healthy adults. Read More
Are you trying to stay on top of developments in CAR T therapies? Drug resistance? Emerging compounds? Updates from certain regulatory agencies? Want to be the first to learn about new biomarkers or business deals? You can still find these articles in the daily BioWorld e-newsletters or on the website, but if you’re laser-focused on a specific topic, we have a way to highlight the news you need as it happens, whether we’ve published a full-length feature story or a brief update. You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Happy holidays! Read More
